JOINT FILING AGREEMENTJoint Filing Agreement • May 20th, 2025 • Venrock Healthcare Capital Partners III, L.P. • Pharmaceutical preparations
Contract Type FiledMay 20th, 2025 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common stock of CytomX Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
JOINT FILING AGREEMENTJoint Filing Agreement • April 2nd, 2025 • Venrock Healthcare Capital Partners III, L.P. • Biological products, (no disgnostic substances)
Contract Type FiledApril 2nd, 2025 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common stock of Surrozen, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.